UNSPSC 51143013: Centrophenoxine or meclofenoxate

This classification denotes a neuroprotective agent and nootropic agent with the molecular formula C12H16ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C76QQ2I0RG, chemically known as acetic acid, (p-chlorophenoxy)-, 2-(dimethylamino)ethyl ester, hydrochloride but generally known as meclofenoxate, which bears US NIH Compound Identifier 4039. European Medicines Agency schedules Meclofenoxate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08679MIG.

World Health Organization schedules meclofenoxate in its Anatomical Therapeutic Chemical (ATC) Classification. MECLOFENOXATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CN(C)CCOC(=O)COC1=CC=C(C=C1)CL.

UNSPSC 51143013 Centrophenoxine or meclofenoxate, a Commodity code, covers a pharmaceutical active ingredient used in nootropic and cognitive-enhancement formulations. State and local governments procure this substance primarily through public health departments, correctional health services, and institutional medical supply chains for use in compounded medications and clinical protocols where cognitive support is clinically indicated. The code encompasses the raw chemical compound in pharmaceutical-grade form, typically sourced through licensed pharmaceutical distributors and chemical suppliers qualified to meet USP or equivalent pharmacopeial standards.

No recent state or local contract opportunities appear in the available procurement records for UNSPSC 51143013. The code's narrow pharmaceutical-chemical scope and specialized clinical application make it a low-activity category in state and local procurement, with demand concentrated in larger state health systems and corrections departments rather than distributed across general municipal or county purchasing offices. When activity does occur, it typically flows through standing-order agreements with established pharmaceutical wholesalers or chemical suppliers rather than open competitive solicitation, limiting visibility in standard RFP and IFB channels.